Forrester Announces Full Conference Agenda For Technology & Innovation Summit EMEA 2024
3.9.2024 11:00:00 EEST | Business Wire | Press release
Forrester (Nasdaq: FORR) today announced the full conference agenda for Technology & Innovation Summit EMEA, held in London and digitally, October 9–11, 2024. While the potential of generative AI (genAI) to enhance efficiency and innovation is evident, tech leaders must strike the right balance, leveraging emerging technologies like automation and genAI to fuel innovation while also making sure to avoid stifling it. They need to understand where AI can make the most significant impact and identify the necessary resources for effective implementation.
At this year’s Technology & Innovation Summit EMEA, technology, data and analytics, and cybersecurity leaders will have insight into new research and learn best practices to achieve high-performance IT, understand the ethical, safe, and secure ways to take advantage of new technologies that are fundamental to building trust with their customers, and assess how to use AI as a catalyst for innovation and change.
Noteworthy keynotes and sessions include:
- Generative AI As A Forcing Factor For Change. In this keynote, technology leaders will learn how to maximise their investment in genAI to scale beyond a single use case.
- Unleash Your Potential With High-Performance IT. This keynote will cover how to align and adapt to changing business dynamics with high-performance IT.
- Embrace Trust, Adaptivity, And Alignment for AI Success. In this keynote, leaders will understand how to address the AI bottleneck by breaking down operational and data silos.
- A Fun (Yes, Really) Crash Course In EU AI Act Compliance. This session will reveal which initiatives and capabilities to prioritise and outline a dedicated roadmap to help tech leaders prepare for the impending EU AI Act.
- Staying Resilient In A Fluid Technology And Threat Landscape. In this keynote, cybersecurity leaders will explore how to approach AI practically, balancing risk and opportunity.
- AI, Low-Code, And The End Of Software Development As We Know It. This keynote will discuss the impact of genAI on the software development lifecycle and explore the emergence of application generation platforms infused with both predictive and generative AI.
“Tech, data, and security leaders in Europe are under tremendous pressure to deliver on AI investments,” said Pascal Matzke, Forrester VP and research director and T&I EMEA event host. “At Technology & Innovation EMEA, leaders will learn how to overcome common obstacles associated with the adoption of genAI and how leaders can effectively steer, align, and motivate their business to successfully scale their genAI initiatives.”
In-person attendees will experience facilitated discussions, consulting workshops, and special programmes, including the Women’s Leadership Programme; the Executive Leadership Exchange, an exclusive programme targeted at C-level leaders; and several diversity and inclusion sessions. Digital attendees will have access to all conference sessions and sponsors via the event platform.
Resources:
- Register to attend Forrester’s Technology & Innovation Summit EMEA 2024.
- View the full agenda and speakers for Technology & Innovation Summit EMEA 2024.
- Follow @Forrester and #ForrTech for updates.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the centre of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; and the shared wisdom of our clients. To learn more, visit Forrester.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903845085/en/
Contacts
Press contacts:
Hannah Segvich
hsegvich@forrester.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom